Table 3.
Immunomodulators evaluated in woodchucks for safety and antiviral efficacy against hepatitis B virus
|
Immunomodulator
|
Compound name
|
Brand name
|
Ref.
|
| IFN-α | [192,226,228,229] | ||
| RIG-I/NOD2 agonist | SB 9200 | Inarigivir | [227] |
| TLR7 agonist | GS-96201 | Vesatolimod | [173] |
| APR002 | [225] | ||
| RG7854 | [38] | ||
| TLR8 agonist | GS-9688 | Selgantolimod | [174] |
| TLR9 agonist | CpG-ODN | [234] | |
| TLR9-dependent and -independent pathways | AIC649 | [235] | |
| JVRS-1002 | [175] | ||
| Viral gene expression inhibitor | RG7834 | [226] | |
| Immune checkpoint inhibitor | Anti-PD-L1 | [236] |
1
Treatment delayed hepatocellular carcinoma onset in woodchucks.
2
Treatment inhibited formation of new liver tumors in woodchucks.
See text for more details. Anti-PD-L1: Antibody against programmed death-ligand 1; CpG-ODN: CpG oligodeoxynucleotide, a short single-stranded synthetic DNA molecule containing unmethylated deoxycytosine-deoxyguanosine (CpG) motifs; IFN-α: Interferon alpha; JVRS-100: Complex of non-coding plasmid DNA and cationic liposomes; NOD2: Nucleotide-binding oligomerization domain-containing protein 2; RIG-I: Retinoic acid-inducible gene I; TLR: Toll-like receptor.